-
May 20, 2020 A team of researchers led by Ajou’s Prof. Lee Beom-jin (College of Pharmacy) successfully identified a new mechanism for optimizing the efficacy of cancer cell therapies. Their study, entitled “Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model,” was published in The Journal of Controlled Release, a prestigious publication for pharmaceutical and pharmacological research. Prof. Lee’s team sought to design fatty acid-conjugated albumin nanoparticles (ANPs) of different chain lengths so as to test and compare their anticancer activities in mice with overactive free-fatty acid receptors (FFARs) and HCT116 human colorectal cancer xenografted. ANPs conjugated with fatty acids of different chain lengths (C4 for butyric acid; C18 for stearic acid) exhibited physicochemical characteristics and anticancer activity different from those of self-assembled structures. In particular, ANPs with long-chain fatty acids including doxorubicin, a known anticancer drug, activated interaction with FFARs in the HCT 116 human colorectal cancer xenograft mouse model, providing better anticancer activity and fewer side effects than either nanoparticles without fatty acids conjugated or ANPs with short-chain fatty acids. Prof. Lee explained: “The uniqueness of our achievement lies in our fattigation platform technology, which conjugates fatty acids of diverse lengths with large molecules. We expect to apply this technology to experiments with fatty acids of varying lengths and accelerate the research on and development of new drug delivery systems, including diverse target cancer therapies and drugs with improved solubility.” An illustration of how Prof. Lee’s team’s technique was applied to improve the efficacy of an anticancer drug in a mouse model
-
428
- 작성자OI***
- 작성일2020-06-16
- 7746
- 동영상동영상
-
May 15, 2020 J&J PharmaTech, a LINC Project group of Ajou University, visited the COVID-19 clinic at Ajou University Hospital to deliver snacks, drinks, and 3,000 personal hand sanitizers to the staff. J&J PharmaTech is a startup run by Jeong Hye-jeong, currently enrolled as a student in the Graduate School of Clinical Pharmacy and Pharmaceutics. The Graduate School revealed that Jeong, along with the school’s dean, Kim Su-dong, and other school officials visited Ajou University Hospital on May 7 to thank the medical staff and deliver donations in person. They were welcomed by the hospital’s president, Dr. Han Sang-uk, and other medical workers on site. Neo Trans, the company operating the Sinbundang Line on the metropolitan transit network across Seoul and Gyeonggi-do, also joined in with delivery of the donations. Jeong explained: “As a LINC Project group of Ajou University’s bio and healthcare industrial cooperation center (ICC), we wanted to do something for the medical staff at the university hospital working on the front line in the current COVID-19 crisis, and thought bringing 3,000 sanitizers was the way to do it.” The ICCs at Ajou University were established with the mission of promoting the University’s research strengths in partnership with local businesses. Faculty members and local firms participate in R&D projects in biotechnology and healthcare, smart mobility, new and renewable energy, artificial intelligence (AI) and big data. Ajou continues to aid local businesses through a wide range of support, including R&D infrastructure, advice, and personnel training.
-
426
- 작성자OI***
- 작성일2020-06-16
- 7020
- 동영상동영상
-
-
424
- 작성자OI***
- 작성일2020-06-16
- 6986
- 동영상동영상
-
May 12, 2020 A delegation of ROK Air Force officers, including the Air Force Chief of Staff, visited Ajou University to discuss matters pertaining to the Department of Military Digital Convergence and terms of cooperation. On May 12, ROK Air Force Chief of Staff, Won In-choul, and other Air Force officers met with a group of faculty members, including University president Park Hyung-ju, in the president’s office at Yulgok Hall. Also present were Prof. Lim Jae-seong, Vice-President of Industrial-Academic Cooperation and Dean of the Department of Military Digital Convergence; Prof. Kim Sang-in, Provost of the College of Information Technology; and Prof. Kim Jeong-sik from the Department of Military Digital Convergence. After exchanging greetings at Yulgok, the officers and the professors then moved to Yeonam Hall to discuss the matters at hand. The Department of Military Digital Convergence came into being in 2015 under a contract between Ajou and the ROK Air Force. All students enrolled in the department are on four-year full scholarships from the Air Force, on the condition that they will serve as commissioned officers for seven years after graduation. Upon completion of all seven years, they may choose to continue their careers in the military or find new opportunities in the defense industry or research. The ROK Air Force Chief of Staff and other high-level officers have been visiting Ajou every year since the department’s creation to meet and encourage the students. This year’s event was downsized from usual in terms of scope and reach due to COVID-19 and the need for social distancing. #What to Study: Department of Military Digital ConvergenceExcerpted from Ajou Insight Spring Edition, 2018
-
422
- 작성자OI***
- 작성일2020-06-16
- 6950
- 동영상동영상
-
May 12, 2020 A team of researchers led by Ajou University’s Prof. Kim Jong-hyun has unraveled the mechanism behind the design of a conjugated polymer. Capable of maximizing conductivity, these polymers are emerging as key next-generation components for electronics. The team included two professors from Ajou - Kim (Dept. of Applied Chemistry and Biological Engineering and Graduate Dept. of Molecular Science and Technology, pictured) and Seo Hyung-tak (Dept. of Materials Science and Engineering and Graduate Dept. of Energy Systems) - as well as Prof. Kim Bong-gi of Konkuk University and Prof. Park Hui-joon of Hanyang University. The team’s study was published as part of the online version of Advanced Functional Materials, dated May 4. Entitled “Unraveling Doping Capability of Conjugated Polymers for Strategic Manipulation of Electric Dipole Layer toward Efficient Charge Collection in Perovskite Solar Cells,” the article also featured Yoon Sang-eun, currently enrolled in the postgraduate program in the Department of Materials Science and Engineering at Ajou, as principal investigator. The conjugated polymers at the heart of the article are organic compounds recently drawing significant attention as the potential next-generation alternative to semiconductors. These conductive organic compounds boast properties superior to those of inorganic ones. Chemical doping, in particular, can enhance the conductivity of these polymers to a par with that of metals, making them even more likely as a candidate material for dipoles in electronic devices. These polymers also have the added benefits of being lightweight, pliable, and not so costly to manufacture. The team’s work is noteworthy for unraveling the exact mechanism behind the design of the conjugated polymers, and particularly why they are so highly conductive. The researchers identified the skeleton of the conjugated polymer capable of exchanging charges at maximum efficiency with the dopant (a substance added to the semiconductor-manufacturing process). They also introduced a substituent able to optimize diffusion of the dopant, creating a highly conductive (200 S/cm) membrane and determining the doping mechanism. The team then added the highly conductive conjugated polymers to the hole transporting layer to develop a high efficiency (20 percent or more) perovskite solar cell. Prof. Kim commented: “Our latest study documents the groundbreaking discovery of a new mechanism that can dramatically improve the conductivity of polymers. Our findings will lead to the development of polymer-based, pliable and stretchable highly conductive dipoles.” The study was possible with support from the Ministry of Education’s University-Centered Research Lab Support Program (for Molecular Science & Technology Research Center).
-
420
- 작성자OI***
- 작성일2020-06-16
- 6802
- 동영상동영상
-
Prof. Park Rae-woong (Dept. of Biomedical Informatics) at Ajou University’s School of Medicine has joined the growing number of research teams worldwide analyzing big data in an attempt to fight COVID-19. To that end, the professor has teamed up with the Bill & Melinda Gates Foundation. With the new flow of funding from the foundation, Prof. Park and his team intend to convert COVID-19 clinical testing data into medical big data to be shared with medical professionals and researchers worldwide. The Bill & Melinda Gates Foundation is a well-known charity fund established and run by Bill Gates, the founder of Microsoft, and his wife, Melinda. Prof. Park will spend the seven months from March 26 to October 1 this year converting the COVID-19 clinical test data from two general hospitals in the Daegu-Gyeongbuk region into a medical big data platform based on the common data model (CDM). The CDM renders patients’ digital medical data anonymous and standardized on a par with the global standard. Using such a model, researchers worldwide can develop analytical programs, also in line with the global standard, and share them with other participating researchers and organizations in return for analyzed statistics. The CDM, in other words, simultaneously ensures the protection of privacy and the multiplication of useful data and resources for researchers. Prof. Park and his team expect to achieve timely conversion of COVID-19 medical data using their platform for comprehensive analysis of big data (“FeederNet”) and thereby enable medical and science communities worldwide to identify the key characteristics and risk factors of the disease, and gain a better understanding of the effects and side effects of the diverse treatments being attempted. “We expect the latest partnership to promote the global community’s understanding of COVID-19, generate real-world evidence on the disease, and foment collaboration among researchers worldwide toward finding solutions,” said Prof. Park. As leader of the Federated E- Health Big Data for Evidence Renovation Network, a major national R&D project funded by Korea’s Ministry of Trade, Industry and Energy, Prof. Park has already been standardizing clinical big data from 63 medical institutions across the country. As a well-known medical big data expert, Prof. Park is also one of the founding members of Observational Health Data Sciences and Informatics (OHDSI), a multi-agency research network that encompasses over 200 research institutes worldwide. OHDSI has helped to convert clinical data on over two billion people worldwide into a CDM. #Prof. Park’s Column: “[Ajou Insights] Medicine and Big Data”
-
418
- 작성자OI***
- 작성일2020-05-15
- 7406
- 동영상동영상
-
An interview with Park Hyung-ju, President of Ajou University, has been published in the April 25 edition of JoongAng Sunday. The interview took place in the president’s office on April 8. President Park was asked a number of questions in the interview concerning the founding philosophy and history of the university, the current status of online learning and future plans, the Blue Semesters, his own philosophy on education, and the impact of COVID-19 on learning. Explaining that “universities are where we learn how to learn,” President Park emphasized that university lectures should evolve into “thinking classes” with “blended learning” programs that cater to student capabilities, majors and different learning conditions in both online and offline environments. “Research, education, and industrial-academic collaboration are crucial,” said Park, as “research produces knowledge, education imparts that knowledge, and industrial-academic collaboration applies that knowledge.” He added: “We will change our curriculum so that those majoring in the humanities will also learn coding and engineering majors will also explore the humanities.” Check out the May issue of Monthly JoongAng to read the interview. #Go to the JoongAng Sunday interview article
-
416
- 작성자OI***
- 작성일2020-05-15
- 7324
- 동영상동영상
-
The bio and healthcare industrial cooperation center (ICC) at Ajou University has recently signed a memorandum of understanding (MOU) with Erom to establish a partnership for the creation and joint management of a new immunology research center. The ICC (led by Prof. Kim Su-dong, College of Pharmacy) announced that it entered the partnership with Erom Company on April 21. The parties have agreed to work closely on joint organization and management of an immunology research center, particularly focusing on analyzing immunity-boosting materials and developing new products. Kim Sang-min, CEO of Erom (Ajou Class of 1992, history) remarked: “This MOU gives us an opportunity to work with Ajou University’s research team on researching, developing, testing and commercializing new immunity-boosting products. I hope this partnership will enable us to bring the benefits of novel products to more people.” The ICC and Erom will particularly work together on basic and clinical research on a rice bran extract (“Erom 4”), which Erom’s researchers have been studying for years for its ability to boost the human immune system. The ICCs are clusters, created by Ajou University, to foster collaboration with local businesses and industries on areas of and discoveries in science in which the university’s researchers specialize. There are four areas of specialization: bio-health care, smart mobility, new and renewable energy, and AI and big data. The university provides the necessary infrastructure, advice, and human resource development tools that local businesses need to support their growth.
-
414
- 작성자OI***
- 작성일2020-05-15
- 7439
- 동영상동영상
-
A team of researchers led by Professor Seo Hyeong-tak of Ajou University has developed an artificial synapse for tactile perception. The new device, which emulates tactile perceptions involving touch and nerves, features a hetero-junction of oxides. Expected applications include skin-attached electronics and artificial intelligence (AI) sensors. Prof. Seo (Dept. of Materials Science and Engineering / Graduate Dept. of Energy Systems, pictured) and his team’s work was published under the title, “An artificial piezotronics synapse for tactile perception,” in an online issue of Nano Energy on April 15, 2020. Also on the team from Ajou University were Prof. Kim Sang-wan (Dept. of Electrical and Computer Engineering) and Dr. Mohit Kumar (researcher, Dept. of Materials Science and Engineering). Of the five senses humans have at their disposal, tactile perception involves the signals stimulated by a touch traveling from the stimulus receptor at the terminal of the skin to cranial nerves via the neural network. Humans are able to discern an incredibly wide range of touches on their skin. Combined with emotions of varying depths, these tactile perceptions can become part of human memory. An artificial synapse that emulates the human tactile perception therefore epitomizes a highly sophisticated technology capable of detecting the wide variety of touches exerted from the outside world with finesse and precision, saving perceptions thereof, and retrieving them in a memory-like fashion. Prof. Seo’s team achieved such an advanced artificial synapse, featuring a hetero-junction of nickel and zinc oxides (NiO and ZnO) that emulates tactile stimulation of nerves. Specifically, the synapse was designed to emulate how hair detects changes in external pressure using a vertically structured sensor featuring the hetero-junction of oxides. It is this sensor that produces changes in the current-voltage curve in response to changing intensity and directions of pressure in a fashion similar to how the human body perceives touch. Concept of a very transparent and flexible artificial synapse that emulates environment-adaptable tactile perceptions The team’s discovery is all the more significant due to its ability to remember tactile changes in electric currents, in the form of conserved charges, for a certain period of time, in a fashion similar to non-volatile memory. The artificial synapse is capable of emulating all the typical functions of actual neuron synapses, such as perceiving changes in signals, whether in intensity or over time and in size. The invention therefore bears much functional similarity to an actual in-vivo tactile neural circuit. Prof. Seo explained: “We created a test touch pad with multiple artificial synapses arranged on it, and discovered that the pad is capable of effectively detecting temporal-spatial information from external variables, such as the amplitude and duration of stimuli. We also demonstrated that the synapse is capable of discerning different pressure patterns.” The artificial neural circuit architecture that simulates sensory nerve functions from touch to the brain requires the integration of a pressure sensor, a connecting cable, and an artificial synapse. This is an extremely sophisticated technology that involves quite complex machinery and ultra-low energy consumption. Prof. Seo’s team has created an ultra-energy-light and high-precision artificial synapse, using a relatively simple manufacturing process, that can adjust output in response to variations in tactile input. Prof. Seo further commented: “The artificial synapse we developed this time is comparatively less complex and consumes less energy than other preexisting and similar tactile circuits. At the same time, it provides superior environment-adaptable detections of touch. We anticipate that our invention can be made into various applications, including AI sensors, skin-attachable electronics, robotics, and prosthetic limbs for people with disabilities.” The study was conducted with support from the New Future Device and Original Technology Development Program and the Basic Research Support Program for Established and New Projects , sponsored by the Ministry of Science and ICT and the National Research Foundation of Korea, respectively.
-
412
- 작성자OI***
- 작성일2020-05-15
- 7575
- 동영상동영상
-
-
410
- 작성자OI***
- 작성일2020-05-15
- 7196
- 동영상동영상
-
A team of Ajou University researchers led by Prof. Yoon Tae-jong has succeeded in developing a treatment for colorectal cancer using gene editing. The cure is specifically meant for colorectal cancer patients with gene mutations on whom other more common therapies do not work. Prof. Yoon (College of Pharmacy) teamed up with Prof. Cho Young-seok of the Catholic University (Department of Internal Medicine, College of Medicine) to develop a gene editing technique that involves mounting a gene-editing structure onto a nano-size carrier to edit genetic mutations that complicate colorectal cancer treatment. The result of their collaboration was published in an online issue of Nano Research, a widely recognized international journal, on April 4, 2020, with the title, “Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer.” Cetuximab is a widely used treatment for colorectal cancer, but there are also a significant number of patients whose KRAS gene mutation renders them resistant to the drug. The number of patients newly diagnosed with colorectal cancer is on the rise worldwide due to the increase in modern and unhealthy diets. Finding effective cures to this particular cancer is therefore a popular and important topic of pharmaceutical research, with much of the current research focusing on antibodies. The conventional approach to treatment is to introduce a drug that binds to the EGFR receptor to inhibit the growth and survival of cancerous cells. Nearly 60 percent of colorectal cancer patients, however, are genetically resistant to this type of treatment. The prognosis for these patients with the KRAS gene mutation is rather dim. Although a growing number of researchers focus on finding alternative cures for patients with the KRAS gene mutation, that particular genetic mutation facilitates patient relapse, raising the demand for a more fundamental therapeutic approach. Although scientists have speculated that gene editing could pave the way to a useful alternative, they have been struggling to overcome the resulting inefficiency, as these protein-based genetic editing techniques turn quite volatile in vivo. Prof. Yoon’s team thus introduced this breakthrough, whereby they demonstrated that mounting the gene-editing protein onto a nano-size carrier could effectively treat colorectal cancer. The team applied a nano-liposome structure as a carrier for the gene-editing technique that can get to and remove the mutated KRAS gene. By inserting a cancer-targeting antibody into the surface of this nano-structure, the researchers were able to maximize stability and efficacy of the gene editing. In an in-vivo test, the gene-editing structure had an efficiency of 60 percent in targeting cancerous tissues. The technique had a definitively more therapeutic effect on targeted animals as compared to the control group. Prof. Yoon explained: “Existing gene editing techniques rely on viral carriers that require adaptation in vivo before their effects appear. This meant low efficiency and increased risk of off-target editing. Although protein-based gene editing techniques have emerged as an alternative, the fact that these protein carriers were broken down in vivo by enzymes meant the targeting efficiency was inevitably compromised as well.” His team therefore came up with a nano-structure capable of in-vivo adaptation to enhance gene editing stability and efficiency, thereby significantly improving the overall therapeutic value of the gene editing technology in cancer treatment. Prof. Yoon commented: “At present, gene editing in the context of cancer treatment is mostly used to regulate the activity of immune cells in vitro. With our discovery, we expect the medical community to be able to inject gene-editing structures directly into patients’ bodies to maximize the effect of treatment.” The KRAS gene mutation accounts for complications in treatment beyond colorectal cancer, to include treatment for pancreatic, lung, ovarian and other types of cancer. Nano-gene editing is therefore desperately needed to enable cancer patients to receive the life-saving treatment they need. Prof. Yoon has been researching nano-materials capable of effectively delivering diverse biomaterials into cells and tissues for the last two decades. In recent years, he has concentrated on adapting nano-technology to gene editing so as to enhance the latter’s in-vivo stability and cell permeability and also to facilitate localized treatment. Prof. Yoon is also the CEO of Moogene Medi Inc., part of N4U Tech Holdings Inc., which leads Ajou University’s industrial-academic collaboration programs. He intends to have Moogene Medi organize the clinical trials for his team’s groundbreaking discovery.
-
408
- 작성자OI***
- 작성일2020-05-15
- 7068
- 동영상동영상
-
A team of researchers at Ajou University, including Professors Choi Sang-dun and Kim Wook, has found a cure for several autoimmune inflammatory diseases. The team has successfully demonstrated the efficacy of their product in treating diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The team’s groundbreaking paper was published in an online issue of Biomaterials, an international journal, on March 17, 2020. Professor Choi (Dept. of Molecular Science and Technology, Graduate Dept. of Life Sciences) led the work as the corresponding author, with participation from other Ajou faculty members, including Profs. Kim Wook (Molecular Science and Technology), Suh Chang-hee (Dept. of Rheumatology, School of Medicine), and Kim Soon-sun and Cheong Jae-youn (both Dept. of Gastroenterology, School of Medicine). Research Professor Masaud Shah and Prof. Lee Sang-ho (Division of Nephrology, Department of Internal Medicine at Kyung Hee University Hospital at Gangdong) also participated. Kim Gi-young and Asma Achek, both studying molecular science and technology at Ajou, were also listed as co-principal investigators. The researchers developed a peptide-based treatment for autoimmune inflammatory diseases, and demonstrated its efficacy in treating non-alcoholic steatohepatitis (NASH), SLE, RA, eczema and sepsis in animals. An autoimmune disease is an abnormal immune response of the body to its own tissues or cells. There are approximately 80 autoimmune diseases that have been identified so far. Inflammatory diseases refer to a broad array of diseases in which inflammation is a major symptom, and can include NASH, sepsis, and even Alzheimer’s. There are mainly two mechanisms by which autoimmune and inflammatory diseases occur: either in response to an infection by an outside pathogen or as a non-infectious response to substances generated within the immune host itself. Abnormal activation of the Toll-like receptors (TLRs) is involved in both cases, but not much more is known. The Ajou team of researchers has discovered a peptide (MIP2) that can inhibit the activity of TLRs across a wide range of situations to rein in inflammatory cytokines. Prof. Choi explained: “We have discovered that injecting this peptide, MIP2, into test models cured them of NASH, SLE, RA, eczema, and sepsis. In addition, we are researching and testing the effect of this peptide on inhibiting inflammasomes and thereby possibly treating other inflammatory diseases, including Alzheimer’s, type-II diabetes, and multiple sclerosis.” The project was organized with support from the R&D-Centered Hospital Support Program of the Ministry of Health and Welfare, as well as the Basic and Original Research Support Program, co-sponsored by the Ministry of Science and ICT and the National Research Foundation of Korea.
-
406
- 작성자OI***
- 작성일2020-05-15
- 7180
- 동영상동영상
